217 related articles for article (PubMed ID: 19270316)
1. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
Kastrup J; Johansen JS; Winkel P; Hansen JF; Hildebrandt P; Jensen GB; Jespersen CM; Kjøller E; Kolmos HJ; Lind I; Nielsen H; Gluud C;
Eur Heart J; 2009 May; 30(9):1066-72. PubMed ID: 19270316
[TBL] [Abstract][Full Text] [Related]
2. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
[TBL] [Abstract][Full Text] [Related]
3. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease.
Wang Y; Ripa RS; Johansen JS; Gabrielsen A; Steinbruchel DA; Friis T; Bindslev L; Haack-Sørensen M; Jørgensen E; Kastrup J
Scand Cardiovasc J; 2008 Oct; 42(5):295-302. PubMed ID: 18615353
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of YKL-40 increases in patients with acute myocardial infarction.
Nøjgaard C; Høst NB; Christensen IJ; Poulsen SH; Egstrup K; Price PA; Johansen JS
Coron Artery Dis; 2008 Jun; 19(4):257-63. PubMed ID: 18480670
[TBL] [Abstract][Full Text] [Related]
5. Plasma YKL-40 predicts 10-year cardiovascular and all-cause mortality in individuals with type 2 diabetes.
Lin CH; Li HY; Jiang YD; Chang TJ; Chuang LM
Clin Endocrinol (Oxf); 2013 Aug; 79(2):185-91. PubMed ID: 22901243
[TBL] [Abstract][Full Text] [Related]
6. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease.
Mathiasen AB; Harutyunyan MJ; Jørgensen E; Helqvist S; Ripa R; Gøtze JP; Johansen JS; Kastrup J
Scand J Clin Lab Invest; 2011 Sep; 71(5):439-47. PubMed ID: 21827355
[TBL] [Abstract][Full Text] [Related]
7. Serum YKL-40 levels in patients with coronary artery disease.
Kucur M; Isman FK; Karadag B; Vural VA; Tavsanoglu S
Coron Artery Dis; 2007 Aug; 18(5):391-6. PubMed ID: 17627189
[TBL] [Abstract][Full Text] [Related]
8. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.
Zheng JL; Lu L; Hu J; Zhang RY; Zhang Q; Chen QJ; Shen WF
Atherosclerosis; 2010 Jun; 210(2):590-5. PubMed ID: 20056225
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.
Harutyunyan MJ; Mathiasen AB; Winkel P; Gøtze JP; Hansen JF; Hildebrandt P; Jensen GB; Hilden J; Jespersen CM; Kjøller E; Kolmos HJ; Gluud C; Kastrup J;
Scand J Clin Lab Invest; 2011 Feb; 71(1):52-62. PubMed ID: 21108561
[TBL] [Abstract][Full Text] [Related]
10. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
11. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.
Rathcke CN; Raymond I; Kistorp C; Hildebrandt P; Faber J; Vestergaard H
Int J Cardiol; 2010 Aug; 143(1):35-42. PubMed ID: 19223085
[TBL] [Abstract][Full Text] [Related]
12. Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.
Schroder J; Jakobsen JC; Winkel P; Hilden J; Jensen GB; Sajadieh A; Larsson A; Ärnlöv J; Harutyunyan M; Johansen JS; Kjøller E; Gluud C; Kastrup J
J Am Heart Assoc; 2020 Mar; 9(5):e014634. PubMed ID: 32114892
[TBL] [Abstract][Full Text] [Related]
13. Increased YKL-40 levels in patients with isolated coronary artery ectasia: an observational study.
Erdoğan T; Kocaman SA; Çetin M; Durakoğlugil ME; Kırbaş A; Canga A; Yılmaz A; Doğan S; Çiçek Y
Anadolu Kardiyol Derg; 2013 Aug; 13(5):465-70. PubMed ID: 23728225
[TBL] [Abstract][Full Text] [Related]
14. Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease.
Harutyunyan M; Johansen JS; Mygind ND; Reuter SB; Kastrup J
Biomark Med; 2014; 8(8):977-87. PubMed ID: 25343670
[TBL] [Abstract][Full Text] [Related]
15. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
16. YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients.
Höbaus C; Tscharre M; Herz CT; Pesau G; Wrba T; Koppensteiner R; Schernthaner GH
Atherosclerosis; 2018 Jul; 274():152-156. PubMed ID: 29783062
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide.
Lyngbæk S; Winkel P; Gøtze JP; Kastrup J; Gluud C; Kolmos HJ; Kjøller E; Jensen GB; Hansen JF; Hildebrandt P; Hilden J;
Eur J Prev Cardiol; 2014 Oct; 21(10):1275-84. PubMed ID: 23723326
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy associated plasma protein-A as a marker for myocardial infarction and death in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial.
Iversen KK; Teisner B; Winkel P; Gluud C; Kjøller E; Kolmos HJ; Hildebrandt PR; Hilden J; Kastrup J;
Atherosclerosis; 2011 Jan; 214(1):203-8. PubMed ID: 21093861
[TBL] [Abstract][Full Text] [Related]
19. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
20. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
